The lack of aspirin resistance in patients with coronary artery disease

Journal of Translational Medicine

Volumn 14, Issue 1, 2016, Pages

  Homoródi, Nóra ^a   Kovács, Emese G ^a   Leé, Sarolta ^b   Katona, Éva ^a   Shemirani, Amir H ^a   Haramura, Gizella ^a   Balogh, László ^a   Bereczky, Zsuzsanna ^a   Szoke, Gabriella ^c   Péterfy, Hajna ^c   Kiss, Róbert G ^b   Édes, István ^a   Muszbek, László ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Military Hospital   (Hungary)

^c Diagnosticum Inc   (Hungary)

Author keywords

Aspirin; Coronary artery disease; Cyclooxygenase 1; Cyclooxygenase 2; Platelet; Thromboxane B2

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; THROMBOXANE B2; MESSENGER RNA; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

ACETYLATION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENZYME RELEASE; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; IMMUNOASSAY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING HABIT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY; VERY ELDERLY; WESTERN BLOTTING; BIOSYNTHESIS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED;

ACETYLATION; ADULT; AGED; AGED, 80 AND OVER; ARACHIDONIC ACID; ASPIRIN; CORONARY ARTERY DISEASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; RNA, MESSENGER; THROMBOXANE B2;

EID: 84960873791     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-016-0827-7     Document Type: Article

References (42)

1. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e89S-119S.
2. Patrono C, Rocca B. Aspirin, 110 years later. J Thromb Haemost. 2009;7(Suppl 1):258-61.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
4. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60.
5. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e637S-68S.
6. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373-83.
7. Kulmacz RJ, van der Donk WA, Tsai AL. Comparison of the properties of prostaglandin H synthase-1 and -2. Prog Lipid Res. 2003;42:377-404.
8. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56:387-437.
9. Pettersen AA, Arnesen H, Seljeflot I. A brief review on high on-aspirin residual platelet reactivity. Vascul Pharmacol. 2015;67-69:6-9.
10. Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J. 2010;31:17-28.
11. Kovacs EG, Katona E, Bereczky Z, Homorodi N, Balogh L, Toth E, et al. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals. Thromb Res. 2013;131:320-4.
12. Kovacs EG, Katona E, Bereczky Z, Homorodi N, Balogh L, Toth E, et al. Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods. Thromb Res. 2014;133:811-6.
13. Patrignani P, Tacconelli S, Piazuelo E, Di Francesco L, Dovizio M, Sostres C, et al. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. J Thromb Haemost. 2014;12:1320-30.
14. Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost. 2009;101:151-6.
15. Guthikonda S, Lev EI, Patel R, DeLao T, Bergeron AL, Dong JF, et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost. 2007;5:490-6.
16. Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA. 2002;99:7634-9.
17. Capodanno D, Patel A, Dharmashankar K, Ferreiro JL, Ueno M, Kodali M, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv. 2011;4:180-7.
18. Brown DL, Cai TT, DasGupta A. Interval estimation for a binomial proportion. Stat Sci. 2001;16:101-33.
19. Zsori KS, Muszbek L, Csiki Z, Shemirani AH. Validation of reference genes for the determination of platelet transcript level in healthy individuals and in patients with the history of myocardial infarction. Int J Mol Sci. 2013;14:3456-66.
20. Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. Nat Protoc. 2006;1:1559-82.
21. Birschmann I, Mietner S, Dittrich M, Pfrang J, Dandekar T, Walter U. Use of functional highly purified human platelets for the identification of new proteins of the IPP signaling pathway. Thromb Res. 2008;122:59-68.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-8.
23. Zou H, Yuan C, Dong L, Sidhu RS, Hong YH, Kuklev DV, et al. Human cyclooxygenase-1 activity and its responses to COX inhibitors are allosterically regulated by nonsubstrate fatty acids. J Lipid Res. 2012;53:1336-47.
24. Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013;127:377-85.
25. Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood. 2012;119:3595-603.
26. Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost. 2012;10:1220-30.
27. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984;311:1206-11.
28. van Pampus EC, Huijgens PC, Zevenbergen A, Twaalfhoven H, van Kamp GJ, Langenhuijsen MM. Influence of aspirin on human megakaryocyte prostaglandin synthesis. Eur J Haematol. 1993;50:264-8.
29. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366-72.
30. Blobaum AL, Marnett LJ. Structural and functional basis of cyclooxygenase inhibition. J Med Chem. 2007;50:1425-41.
31. Santilli F, Simeone P, Liani R, Davi G. Platelets and diabetes mellitus. Prostaglandins Other Lipid Mediat. 2015. doi: 10.1016/jprostaglandins.
32. Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation. 2002;105:1620-2.
33. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet. 1999;353:900.
34. Riondino S, Trifiro E, Principessa L, Mascioletti S, Di Renzo L, Gaudio C, et al. Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production. Thromb Res. 2008;122:359-65.
35. Schwartz KA, Schwartz DE, Barber K, Reeves M, De Franco AC. Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med. 2008;6:46.
36. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol. 2005;95:973-5.
37. Meen O, Brosstad F, Khiabani H, Gjertsen E, Lauritsen ME, Pedersen TM, et al. No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography. Scand J Clin Lab Invest. 2008;68:185-91.
38. Huber K, Schror K. High on-treatment platelet reactivity-why should we be concerned? Thromb Haemost. 2013;109:789-91.
39. Fitzgerald R, Pirmohamed M. Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol Ther. 2011;130:213-25.
40. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166:1842-7.
41. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980;17:317-27.
42. Bagoly Z, Homorodi N, Kovacs EG, Sarkady F, Csiba L, Edes I, et al. How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy? Platelets. 2016;27:59-65.